TIGIT Inhibitors Market By Therapy Type (Monotherapy, Combination Therapy); By Cancer Indication (NSCLC, Triple-Negative Breast Cancer, Melanoma, Head & Neck Cancer, Others); By Route of Administration (Intravenous, Others); By End User (Academic Cancer Centers, Oncology Clinics, CROs, Specialty Hospitals); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

TIGIT Inhibitors Market Repositions Around Clinical Validation After Mixed Late-Stage Immuno-Oncology Readouts (Last Updated on: June-2026)

The Global TIGIT Inhibitors Market is projected to grow at a strong CAGR of 22.6% during the forecast period. The market was valued at USD 0.42 billion in 2024 and is expected to reach USD 1.4 billion by 2030.

 

The TIGIT inhibitors market remains a pipeline-led immuno-oncology opportunity rather than an approved standalone drug class. As of 2026, no TIGIT inhibitor has received full FDA approval as an independent commercial therapy, although the target continues to attract interest because of its role in tumor immune suppression. The market has moved from broad checkpoint enthusiasm into a more selective validation phase after several late-stage setbacks in lung and gastrointestinal cancers.

 

TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, is an inhibitory checkpoint receptor expressed on T cells, regulatory T cells, and natural killer cells. By binding CD155 and CD112, TIGIT weakens cytotoxic immune activity and helps tumors avoid immune attack. TIGIT inhibitors are designed to release this brake and restore CD8+ T-cell and NK-cell function, usually in combination with PD-1 or PD-L1 inhibitors.

 

The class is now being judged by incremental benefit over established checkpoint therapy. Biology alone is no longer enough. Future value will depend on whether TIGIT blockade can improve survival, deepen response, or extend durability in tumor settings where PD-1 and PD-L1 therapy remains active but incomplete.

 

Market Structure and Evolution of the TIGIT Development Landscape

The TIGIT inhibitors market includes monoclonal antibodies, Fc-silent antibodies, Fc-enabled antibodies, PD-1/TIGIT bispecific antibodies, and multifunctional immunotherapy constructs. Development is concentrated in non-small cell lung cancer, small cell lung cancer, gastric and gastroesophageal cancers, biliary tract cancer, melanoma, cervical cancer, and other advanced solid tumors.

This is not a mature checkpoint market. PD-1 and PD-L1 inhibitors are already embedded in oncology treatment pathways, while TIGIT inhibitors still need to prove that they add meaningful benefit to those backbones. Most programs are therefore combination-led rather than monotherapy-led.

The field has become more disciplined after mixed Phase III outcomes. Early Phase II signals in PD-L1-high NSCLC created strong momentum, but later studies did not consistently confirm that benefit. This has shifted attention toward better patient selection, bispecific formats, rational ADC combinations, and tumor settings where checkpoint response is present but insufficient.

 

Disease Opportunity and Trial-Relevant Patient Pools

Lung cancer remains the central testing ground for TIGIT inhibitors because PD-1 and PD-L1 therapy is already embedded in NSCLC treatment. Globally, lung cancer accounted for about 2.5 million new cases and 1.8 million deaths in 2022, while the United States is expected to record about 229,410 new lung and bronchus cancer cases in 2026. The TIGIT-relevant population is concentrated in metastatic or locally advanced NSCLC, especially PD-L1-expressing tumors where checkpoint therapy is active but incomplete. This makes NSCLC the most important clinical setting for determining whether TIGIT blockade can add survival or durability benefit beyond established checkpoint-based standards.

The relevant NSCLC pool is narrower than total lung cancer incidence. Most TIGIT programs focus on metastatic or locally advanced disease, PD-L1-expressing tumors, checkpoint-sensitive settings, and patients without actionable driver mutations. Commercial relevance depends on whether TIGIT combinations can beat current PD-1/PD-L1-based regimens in a defined treatment setting.

Gastric, gastroesophageal junction, and esophageal cancers form the next important trial pool. Globally, stomach cancer accounted for about 969,000 new cases in 2022, while esophageal cancer accounted for about 511,000 new cases. In the United States, 2026 estimates include about 31,510 new stomach cancer cases and about 22,530 new esophageal cancer cases. These are smaller markets than NSCLC, but advanced disease has high unmet need and is already an active area for checkpoint combinations.

Biliary tract cancer, melanoma, cervical cancer, and other solid tumors add development breadth. These should be viewed as selective expansion settings rather than broad commercial foundations. TIGIT inhibitors will only matter in these tumors if they show clear additive benefit over existing checkpoint, chemotherapy, targeted therapy, or ADC-based standards.

 

Current Standard of Care and Competitive Pressure

The main challenge for TIGIT inhibitors is the strength of the existing immunotherapy base. PD-1 and PD-L1 inhibitors are widely used across NSCLC, melanoma, renal cell carcinoma, gastric cancer, cervical cancer, hepatocellular carcinoma, and several other tumors. In many settings, they are already combined with chemotherapy, VEGF inhibitors, CTLA-4 inhibitors, or targeted agents.

This creates a high evidence bar. TIGIT inhibition must show better survival, longer progression-free survival, deeper response, or improved durability compared with modern checkpoint regimens. In many trials, the comparator is no longer chemotherapy alone; it is an active PD-1 or PD-L1 standard.

The unmet need remains meaningful in patients with primary resistance, incomplete response, or relapse after checkpoint therapy. However, late-stage experience shows that adding TIGIT blockade to a PD-1/PD-L1 backbone does not automatically improve outcomes. Future programs need sharper clinical hypotheses rather than broad checkpoint layering.

 

Pipeline Assessment: Leading TIGIT Programs and Recent Clinical Outcomes

Tiragolumab from Roche and Genentech was the first anti-TIGIT therapy to receive FDA Breakthrough Therapy Designation in combination with atezolizumab for PD-L1-high metastatic NSCLC. The asset defined early market enthusiasm, but the SKYSCRAPER-01 Phase III study did not meet its overall survival endpoint in PD-L1-high advanced NSCLC. Tiragolumab now functions as both a scientific reference point and a cautionary benchmark for the class.

Ociperlimab from BeiGene, previously partnered with Novartis, was another late-stage TIGIT antibody. Its outlook weakened after disappointing Phase III performance in PD-L1-high NSCLC, and BeiGene moved to discontinue the program. This reinforced the lesson that PD-L1-high selection alone may not be enough to validate TIGIT blockade.

Domvanalimab from Arcus Biosciences and Gilead was designed as an Fc-silent anti-TIGIT antibody. The intent was to block TIGIT signaling while avoiding peripheral regulatory T-cell depletion. Despite its differentiated design, Phase III studies have been challenging. STAR-221 in upper gastrointestinal cancers and STAR-121 in metastatic NSCLC were discontinued for futility, making the asset’s path more selective.

Vibostolimab from Merck was evaluated with pembrolizumab in the KeyVibe program. Multiple Phase III studies were discontinued after futility or safety concerns, and Merck discontinued the vibostolimab development program. This removed one of the most visible large-pharma TIGIT contenders.

Rilvegostomig from AstraZeneca, based on Compugen-derived TIGIT biology, represents a different direction. It is a PD-1/TIGIT bispecific antibody being tested in Phase III settings, including nonsquamous NSCLC and biliary tract cancer. Its relevance comes from integrating both checkpoints into one molecule rather than adding a separate anti-TIGIT antibody to a PD-1/PD-L1 drug.

Earlier and regionally differentiated programs remain active. Akeso’s AK130 combines anti-TIGIT activity with a TGF-β receptor II domain to address multiple suppressive pathways. Agenus’ AGEN1777 and Bio-Thera’s BAT6005 represent additional anti-TIGIT approaches, with BAT6005 retaining IgG1 ADCC function. These assets are less mature, but they show that the field is moving toward differentiated design rather than repeating first-generation antibody models.

 

Clinical Success Factors and Emerging Validation Criteria

The TIGIT market is now benchmarked by survival and durability. The most important endpoints are overall survival, progression-free survival, response depth, duration of response, discontinuation rates, and subgroup performance. Target engagement alone does not define value.

NSCLC has set the toughest benchmark because the treatment landscape is already strong. Pembrolizumab, atezolizumab, chemotherapy-immunotherapy combinations, and durvalumab-based strategies are established in multiple settings. A TIGIT combination must therefore show a visible gain over an active standard, not simply confirm immune activity.

PD-L1-high disease remains relevant, but it is no longer a sufficient enrichment strategy by itself. Future studies may need stronger immune-context selection, including CD155 pathway activity, TIGIT/CD226 balance, T-cell exhaustion patterns, NK-cell activity, or suppressive tumor microenvironment signals. The likely future of the class is subgroup refinement, not broad all-comer checkpoint expansion.

Safety also affects differentiation. Dual checkpoint blockade can increase immune-related toxicity and discontinuation risk. Fc-silent designs and bispecific formats attempt to improve the therapeutic window, but randomized data must still prove that efficacy improves without creating an unacceptable safety burden.

 

Competitive Positioning of Key TIGIT Assets and Platform Strategies

Tiragolumab remains important because it established early TIGIT momentum and gained Breakthrough Therapy Designation. Its late-stage results, however, reduced confidence in first-generation TIGIT antibodies. Ociperlimab and vibostolimab add further evidence that broad TIGIT plus PD-1/PD-L1 combinations carry high development risk.

Domvanalimab’s Fc-silent design offered a more refined immunologic approach, but recent Phase III discontinuations show that engineering alone cannot solve the clinical-positioning problem. Its remaining value depends on whether ongoing or future work identifies a tumor setting where TIGIT dependence is stronger.

Rilvegostomig is currently one of the more strategically relevant assets because it shifts the field toward bispecific checkpoint targeting. If it succeeds, TIGIT may be repositioned as part of an integrated immunotherapy platform rather than a separate add-on antibody. If it fails, confidence in TIGIT as a broad checkpoint target will weaken further.

AK130, AGEN1777, and BAT6005 provide earlier optionality. Their value lies in testing whether multifunctional design, Fc-effector function, or alternative immune-suppression targeting can create a more convincing clinical signal.

 

Key Development Challenges and Commercial Adoption Barriers

The main risk for TIGIT inhibitors is insufficient incremental efficacy over PD-1 and PD-L1 therapy. Recent late-stage failures show that TIGIT biology needs better clinical translation, not just more combination trials.

Patient selection remains unresolved. PD-L1 expression supported early development, but it has not reliably predicted TIGIT success. Without stronger markers of TIGIT pathway dependence, future studies may continue to miss the patients most likely to benefit.

Combination burden also limits the category. TIGIT inhibitors are rarely being developed as monotherapy, and adding another immunotherapy agent can increase toxicity, cost, infusion burden, and trial complexity. Any future product must justify its place against established checkpoint regimens and newer competitors such as ADCs, bispecific antibodies, T-cell engagers, and targeted therapies.

The field also faces confidence risk. Multiple high-profile discontinuations have made sponsors and clinicians more cautious. This does not eliminate the opportunity, but it raises the standard for future programs.

 

Future Commercial Opportunity

The strongest opportunity lies in tumor settings where PD-1 or PD-L1 therapy is active but incomplete. Selected NSCLC populations, upper gastrointestinal cancers, biliary tract cancer, and other immune-responsive tumors remain relevant if TIGIT blockade can show a clear survival or durability advantage.

Commercial relevance will depend on a defined role. A TIGIT asset must improve survival in a selected lung cancer population, strengthen ADC-checkpoint combinations, improve outcomes in gastrointestinal cancers, or benefit patients with a recognizable immune-suppressed phenotype. Broad all-comer development is less attractive after recent failures.

Differentiated formats may now carry more strategic value than standard antibodies. PD-1/TIGIT bispecifics, Fc-silent antibodies, preserved-effector antibodies, and multifunctional constructs may keep the category viable if they improve the balance between immune activation, safety, and efficacy.

 

Future Outlook

The TIGIT inhibitors market remains in a clinical reset phase. The target is still biologically relevant, but the market has moved away from assuming that TIGIT blockade will follow the same path as PD-1 and PD-L1 inhibitors. Recent Phase III setbacks have made additive clinical benefit the defining requirement.

The next phase will be shaped by rilvegostomig Phase III results, remaining domvanalimab analyses, bispecific checkpoint data, ADC-combination strategies, and better subgroup identification. If future programs show survival benefit in selected immune-responsive tumors, TIGIT inhibitors may still become a relevant immuno-oncology class. Without that proof, the category may remain scientifically attractive but commercially constrained.

 

TIGIT Inhibitors Market Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 0.42 Billion
Revenue Forecast in 2030	USD 1.4 Billion
Overall Growth Rate	CAGR of 22.6% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Therapy Type, Cancer Indication, Route of Administration, End User, Geography
By Therapy Type	Monotherapy, Combination Therapy
By Cancer Indication	NSCLC, Triple-Negative Breast Cancer, Melanoma, Head & Neck Cancer, Others
By Route of Administration	Intravenous (IV), Others (in pipeline)
By End User	Academic Cancer Centers, Oncology Clinics, CROs, Specialty Hospitals
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Germany, France, UK, China, Japan, South Korea, Brazil, etc.
Market Drivers	- Rising need for next-gen checkpoint inhibitors - Strong synergy with PD-1/PD-L1 agents - Growing pipeline investments and fast-track designations
Customization Option	Available upon request